SEC Comment Letter 0000000000-23-011859 to Cartesian Therapeutics, Inc. (RNAC) (CIK 0001453687) (RNAC)
Cartesian Therapeutics, Inc. (RNAC) (CIK 0001453687)
Date: Oct. 30, 2023 · CIK: 0001453687 · Accession: 0000000000-23-011859
AI Filing Summary & Sentiment
File numbers found in text: 333-275171
Letter
United States securities and exchange commission logo October 30, 2023 Matt Bartholomae General Counsel Selecta Biosciences, Inc. 65 Grove Street Watertown, MA 02472 Re:Selecta Biosciences, Inc. Registration Statement on Form S-3 Filed October 25, 2023 File No. 333-275171 Dear Matt Bartholomae: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Sarah Griffiths
Show Raw Text
United States securities and exchange commission logo
October 30, 2023
Matt Bartholomae
General Counsel
Selecta Biosciences, Inc.
65 Grove Street
Watertown, MA 02472
Re:Selecta Biosciences, Inc.
Registration Statement on Form S-3
Filed October 25, 2023
File No. 333-275171
Dear Matt Bartholomae:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tamika Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Sarah Griffiths